Newsletter | June 29, 2022

06.29.22 -- One Way To Boost Pipeline Acceleration

New Podcast Episode
Featured Articles
Boosting Pipeline Acceleration With A Strategic Pharma/CDMO Relationship

By working together in strategic partnership, PMs and CDMOs can better manage the flow of pipeline traffic, allowing a biopharma to flex its capacity needs with greater agility and get more candidates to their intended destinations in less time.

How To Build A Strong CRO Partnership And Find Drug Development Success

Building a collaborative and highly engaged partnership with a CRO to optimize study enrollment is critical for a company’s success, particularly with so much reliance on virtual interactions. Here are some tips on how to do just that.

Outsourcing Differences By Company Size — Biologic Drug Substance Manufacturing

ISR split the data from its most recent Biologic API CDMO Benchmarking report by large and non-large respondents to highlight the differences in outsourcing preferences and practices.

Web-Exclusive Content
The Voluntary Improvement Program: FDA Seeks Public Comment On Draft Guidance

The FDA seeks comments on its proposed guidance describing its policy regarding FDA's participation in the Voluntary Improvement Program. The program is facilitated by the Medical Device Innovation Consortium. Comments are due by July 5, 2022.

Industry Insights
Simplifying The Bioprocessing 4.0 Journey

With a practical step-wise approach starting with PAT, plug and play/industry-standard interfaces, data analytics, and improved controls for CPP monitoring, Bioprocessing 4.0 is achievable.

How Technology And Relationships Can Improve Feasibility

Conducting feasibility studies is an essential and necessary step to starting up a clinical trial. The good news is that the whole approach has the ability to change for the better by initiating and adopting some enhancements.

The Advantages And Challenges Of Fixed-Dose Combination Products

Understanding the significant competitive advantages of FDC products and the difficulties and potential pitfalls associated with their development and manufacturing in oral solid dosage forms is critical.

Explore The Nation’s Preeminent Life Sciences Hub

Middlesex County, NJ, is a hotbed for the life sciences, offering a deep talent pool, an extensive R&D presence, and dedicated backing by local government in the form of strategic investment.

Digital Edition
June 2022 Digital Edition

Inside you will find more on:

  • Market Research
  • Diversity & Inclusion
  • China's Biopharma Industry
  • Leadership Advice

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director.